Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

OSE receives approval for Phase II trial of tedopi and opdivo

Histopathogic image of pancreatic adenocarcinoma arising in the pancreas head region. Credit: KGH.

  • OSE Immunotherapeutics

Go Top